e-therapeutics PLC (LON:ETX) has announced the appointment as its chief business officer of Dr Laura Roca-Alonso, formerly with Silence Therapeutics PLC, where the group’s executive chairman used to be in charge.
In a statement, the AIM-listed group said: “Dr Roca-Alonso brings a depth of strategic expertise in advanced therapeutics and platform technologies, encompassing corporate and business development, portfolio strategy, business planning, competitive intelligence and communications.”
READ: e-therapeutics offers up its rapid screening technology in quest to find COVID-19 vaccine
It noted that from 2014 until 2019, she held positions of increasing responsibility at Silence Therapeutics, a publicly listed RNAi company, culminating in her role as VP, Head of Corporate Development, and she was instrumental in the transformation and growth of the business.
Most recently, the group added, she has served as director of Business Development at Gyroscope Therapeutics, a Syncona-backed clinical-stage retinal gene therapy company.
Commenting on the appointment, Ali Mortazavi said: "We are delighted to welcome Laura to the team at e-therapeutics. Her broad experience will be a great asset as we continue to build the company."
Roca-Alonso added: "e-therapeutics has built an impressive network biology-based discovery capability that is being leveraged to gain actionable insights into complex disease and to enable early-stage drug discovery in areas of high unmet need. I am excited to be joining the team at this important time for the company to help maximise the value of its unique platform technologies."